To further encourage the development of treatments for rare diseases, EMA will waive all fees for scientific advice for academia developing orphan medicines.
San Sebastián, Spain, June 4, 2020 - VIVEbiotech, S.L., a gene transfer technologies Contract Development and Manufacturing Organization (CDMO) developing and GMP manufacturing lentiviral vectors, today announces a collaboration with Xyphos Biosciences for the development its CAR-T™ cell therapy for people with hematological cancer.
and the winner is ... Alessandro Aiuti